539 related articles for article (PubMed ID: 15968630)
21. Alterations in the oligodendrocyte lineage, myelin, and white matter in adult mice lacking the chemokine receptor CXCR2.
Padovani-Claudio DA; Liu L; Ransohoff RM; Miller RH
Glia; 2006 Oct; 54(5):471-83. PubMed ID: 16886211
[TBL] [Abstract][Full Text] [Related]
22. Processing of PLP in a model of Pelizaeus-Merzbacher disease/SPG2 due to the rumpshaker mutation.
McLaughlin M; Barrie JA; Karim S; Montague P; Edgar JM; Kirkham D; Thomson CE; Griffiths IR
Glia; 2006 May; 53(7):715-22. PubMed ID: 16506223
[TBL] [Abstract][Full Text] [Related]
23. Normal metabolism but different physical properties of myelin from mice deficient in proteolipid protein.
Jurevics H; Hostettler J; Sammond DW; Nave KA; Toews AD; Morell P
J Neurosci Res; 2003 Mar; 71(6):826-34. PubMed ID: 12605409
[TBL] [Abstract][Full Text] [Related]
24. Transgenic mice expressing polyoma virus large T antigen in astrocytes develop severe dysmyelination of the central nervous system.
Baron-Van Evercooren A; Jensen NA; Wyss MT; Cuzin F; Rassoulzadegan M; Brucher JM; Baron H
Lab Invest; 1992 Jan; 66(1):39-53. PubMed ID: 1309929
[TBL] [Abstract][Full Text] [Related]
25. Investigation of the proteolipid protein promoter activity during demyelination and repair.
Ferent J; Ruat M; Traiffort E
Differentiation; 2013; 85(4-5):182-9. PubMed ID: 23827460
[TBL] [Abstract][Full Text] [Related]
26. Demyelination in a transgenic mouse: a model for multiple sclerosis.
Mastronardi FG; Ackerley CA; Arsenault L; Roots BI; Moscarello MA
J Neurosci Res; 1993 Oct; 36(3):315-24. PubMed ID: 7505836
[TBL] [Abstract][Full Text] [Related]
27. Electrophysiological abnormalities precede apparent histological demyelination in the central nervous system of mice overexpressing proteolipid protein.
Tanaka H; Ikenaka K; Isa T
J Neurosci Res; 2006 Nov; 84(6):1206-16. PubMed ID: 16917838
[TBL] [Abstract][Full Text] [Related]
28. Distinct hypomyelinated phenotypes in MBP-SV40 large T transgenic mice.
Jensen NA; Smith GM; Shine HD; Garvey JS; Hood L
J Neurosci Res; 1993 Feb; 34(3):257-64. PubMed ID: 7681114
[TBL] [Abstract][Full Text] [Related]
29. Identification of the regulatory region of the peripheral myelin protein 22 (PMP22) gene that directs temporal and spatial expression in development and regeneration of peripheral nerves.
Maier M; Berger P; Nave KA; Suter U
Mol Cell Neurosci; 2002 May; 20(1):93-109. PubMed ID: 12056842
[TBL] [Abstract][Full Text] [Related]
30. Focal demyelination in Alzheimer's disease and transgenic mouse models.
Mitew S; Kirkcaldie MT; Halliday GM; Shepherd CE; Vickers JC; Dickson TC
Acta Neuropathol; 2010 May; 119(5):567-77. PubMed ID: 20198482
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor-2 inhibits myelin production by oligodendrocytes in vivo.
Goddard DR; Berry M; Kirvell SL; Butt AM
Mol Cell Neurosci; 2001 Nov; 18(5):557-69. PubMed ID: 11922145
[TBL] [Abstract][Full Text] [Related]
32. Elevated sulfatide levels in neurons cause lethal audiogenic seizures in mice.
van Zyl R; Gieselmann V; Eckhardt M
J Neurochem; 2010 Jan; 112(1):282-95. PubMed ID: 19860853
[TBL] [Abstract][Full Text] [Related]
33. Adult CNP::EGFP transgenic mouse shows pronounced hypomyelination and an increased vulnerability to cuprizone-induced demyelination.
Millet V; Marder M; Pasquini LA
Exp Neurol; 2012 Jan; 233(1):490-504. PubMed ID: 22155618
[TBL] [Abstract][Full Text] [Related]
34. The specificity of the myelin basic protein gene promoter studied in transgenic mice.
Asipu A; Mellor AL; Blair GE
Biochem Biophys Res Commun; 2001 Nov; 288(4):809-18. PubMed ID: 11688980
[TBL] [Abstract][Full Text] [Related]
35. Brain dysmyelination and recovery assessment by noninvasive in vivo diffusion tensor magnetic resonance imaging.
Harsan LA; Poulet P; Guignard B; Steibel J; Parizel N; de Sousa PL; Boehm N; Grucker D; Ghandour MS
J Neurosci Res; 2006 Feb; 83(3):392-402. PubMed ID: 16397901
[TBL] [Abstract][Full Text] [Related]
36. Oligodendrocytes expressing exclusively the DM20 isoform of the proteolipid protein gene: myelination and development.
Spörkel O; Uschkureit T; Büssow H; Stoffel W
Glia; 2002 Jan; 37(1):19-30. PubMed ID: 11746780
[TBL] [Abstract][Full Text] [Related]
37. Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models.
Ortiz E; Pasquini JM; Thompson K; Felt B; Butkus G; Beard J; Connor JR
J Neurosci Res; 2004 Sep; 77(5):681-9. PubMed ID: 15352214
[TBL] [Abstract][Full Text] [Related]
38. Differential myelinogenic capacity of specific developmental stages of the oligodendrocyte lineage upon transplantation into hypomyelinating hosts.
Warrington AE; Barbarese E; Pfeiffer SE
J Neurosci Res; 1993 Jan; 34(1):1-13. PubMed ID: 7678656
[TBL] [Abstract][Full Text] [Related]
39. Delay of myelin formation in arylsulphatase A-deficient mice.
Yaghootfam A; Gieselmann V; Eckhardt M
Eur J Neurosci; 2005 Feb; 21(3):711-20. PubMed ID: 15733089
[TBL] [Abstract][Full Text] [Related]
40. Signal transduction pathways involved in interaction of galactosylceramide/sulfatide-containing liposomes with cultured oligodendrocytes and requirement for myelin basic protein and glycosphingolipids.
Boggs JM; Gao W; Hirahara Y
J Neurosci Res; 2008 May; 86(7):1448-58. PubMed ID: 18189317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
